Aon Review Supports DarioHealth's AI Platform in Cutting Healthcare Costs by Up to 7.2%

DarioHealth Corp. (NASDAQ: DRIO), an AI-powered healthcare technology company, announced that a review by the Managed Care Services Team of Aon plc supports estimated annual healthcare cost reductions of 2.5% to 7.2% for populations using its chronic condition management services. For a representative population of 20,000 covered lives, that translates to approximately $3.8 million to $10.8 million in annual savings, according to the review. The findings matter to Texas businesses and health plans because chronic conditions such as diabetes, hypertension, musculoskeletal issues, and behavioral health needs are among the largest drivers of healthcare spending, and solutions that demonstrably lower costs while improving outcomes could reshape how employers and insurers approach benefits design and population health management.

The Aon review evaluated 17 studies spanning cardiometabolic, musculoskeletal, and behavioral health conditions, including both independently conducted and company-sponsored research. Aon found consistent reported improvements across clinical, behavioral, healthcare utilization, and cost measures, concluding that the evidence supports an association between DarioHealth services and meaningful clinical and financial outcomes. Aon also estimated that management of multiple conditions and access to physicians, which were excluded from the initial calculations, could contribute an additional 1.6 to 2.8 percentage points in savings. However, Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. The full press release is available at https://ibn.fm/IFvLH.

DarioHealth's integrated platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, the platform personalizes care at the individual member level by analyzing biometric, clinical, and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence, and care delivery within a single platform, DarioHealth helps customers address multiple chronic conditions through one solution, a factor that could be particularly relevant for Texas employers seeking to streamline benefits and reduce costly complications.

The announcement comes as Texas continues to grapple with rising healthcare costs and a growing burden of chronic disease. For employers, health plans, and health systems across the state, the Aon review offers a data point suggesting that AI-enabled chronic condition management may deliver measurable returns. The latest news and updates relating to DRIO are available in the company's newsroom at https://ibn.fm/DRIO. The press release was distributed through BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other communications services. For additional information about BioMedWire, visit www.BioMedWire.com.